Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Reiley Pharmaceuticals

2014 FOUNDED
PRIVATE STATUS
Series C LATEST DEAL TYPE
$1.2M LATEST DEAL AMOUNT
Description

Developer of biopharmaceutical products designed to treat pain, cancer and infectious diseases. The company's biopharmaceutical products, enabling patients to recover pain, cancer and infectious diseases.

Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Pharmaceuticals
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • 3749 Buchanan Street
  • Suite 475745
  • San Francisco, CA 94147
  • United States

+1 (408) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Reiley Pharmaceuticals’s full profile, request a free trial.

Reiley Pharmaceuticals Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Angel (individual) 07-Nov-2017 $1.2M 00.000 0000 Completed Startup
2. Angel (individual) 06-Jan-2016 00.00 00.000 00.00 Completed Startup
1. Angel (individual) 29-Aug-2014 $980K $980K 00.000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Reiley Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series C 0,000,000 00.000000 00.00 00.0 00.0 00 00.0 000
Series B 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.00
Series A 2,426,428 $0.000100 $0.04 $0.5 $0.5 1x $0.5 16.18%
To view this company’s complete Cap Table, request access »

Reiley Pharmaceuticals Executive Team (1)

Name Title Board
Seat
Contact
Info
Michael Silber Ph.D Chief Executive Officer & President

Reiley Pharmaceuticals Board Members (1)

Name Representing Role Since Contact
Info
Jeffrey Dunn Self Board Member 000 0000